Compass shares jump as study shows psychedelic-based drug improved depression in cancer patients

Compass shares rose 3% after the London-based mental-health care group reported in a follow-up study that its COMP360 psilocybin treatment, alongside psychological support, led to remission of depression in most cancer patients.